Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
The H1N1 (“Swine flu”) vaccination programme introduced in Scotland in October 2009 had a positive effect in reducing the number of hospital admissions and deaths as a result of H1N1 infection, according to an Article published Online First in The Lancet Infectious Diseases. The study was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme.
The number of deaths from the 2009 H1N1 (“swine flu”) pandemic may be fifteen times higher than the number of laboratory-confirmed deaths previously reported by countries to the World Health Organization (WHO), according to an Article published Online First in The Lancet Infectious Diseases. While estimates of 2009 H1N1-associated deaths have been derived for some countries such as the United States, these are the first estimates of the worldwide number of deaths caused by the pandemic.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD).
In April 2009, the world took notice as reports surfaced of a virus in Mexico that had mutated from pigs and was being passed from human to human. The H1N1 "swine flu," as the virus was named, circulated worldwide, killing more than 18,000 people, according to the World Health Organization. The Centers for Disease Control and Prevention in the United States said it was the first global pandemic in more than four decades.
In 2009, the H1N1 "swine flu" pandemic struck, infecting millions and killing more than 18,000 worldwide, according to the World Health Organization. Though less severe than initially feared, the pandemic highlighted the potential threat of deadly viruses emerging from animals into humans, and the importance of quick and effective public health intervention.
Computer-designed proteins are under construction to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a variety of flu virus strains, including H1N1 pandemic influenza.
Professor Adrian Mulholland and Dr Christopher Woods from Bristol's School of Chemistry, together with colleagues in Thailand, used graphics processing units (GPUs) to simulate the molecular processes that take place when these drugs are used to treat the H1N1-2009 strain of influenza - commonly known as 'swine flu'.
A biomedical informatics researcher who tracks dangerous viruses as they spread around the globe has restructured his innovative tracking software to promote even wider use of the program around the world.
Getting a flu shot during pregnancy provides unanticipated benefits to the baby, according to the authors of a large population-based study examining the issue. Specifically, the study showed that H1N1 vaccination during the pandemic was associated with a significantly reduced risk of stillbirth, preterm birth and extremely small babies at birth.
Inovio Pharmaceuticals, Inc. announced today that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.
College students' social networks influence their beliefs regarding the safety of influenza vaccines and decisions about vaccination, according to a new study in the Journal of Adolescent Health.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.
Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.
University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.
"In a long-awaited study that helped prompt a contentious debate over the wisdom of conducting research that has the potential to help as well as harm, scientists reported Wednesday that they had engineered a mutant strain of [H5N1] bird flu that can spread easily between ferrets -- a laboratory animal that responds to flu viruses much as people do," the Los Angeles Times (Brown, 5/3).
Queen's University and NUI Galway and are leading a clinical trial to investigate the possibility that statins, a drug commonly used to combat cholesterol, might help patients with acute severe respiratory failure.
All Care Inala Medical Centre doctor Michael Ho said flu shots were becoming more popular each year. “Flu seasons tends to begin in late March early April to June,” he said. “More and more people are opting to get vaccinations because they are promoted well within the community.” He added, “It is particularly important for elderly people to be immunized because their immune system is already not at its best…This is also the case for people who have chronic medical conditions like diabetes, severe asthma, or heart disease. With their current condition, if they catch the flu they can end up with a worse outcome.”
Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler.
PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported the launch of the PURE Complete Cleaning, Sanitizing and Disinfecting System.
NanoViricides, Inc. announced today that its previously announced pre-IND Meeting was held with the USFDA on March 29th, 2012, as scheduled. This pre-IND meeting focused on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.